Pulmonary alveolar microlithiasis. World cases and review of the literature

Giuseppe Castellana1, Vito Lamorgese

  • 1Unità Operativa di Pneumologia, Bari, Italy. bepcaste@libero.it

Insights

Pulmonary alveolar microlithiasis (PAM) is a rare lung disease. This review analyzes 424 cases reported globally up to 2001, detailing its epidemiology, clinical features, and diagnostic methods.

Area of Science:

  • Pulmonary Medicine
  • Rare Diseases
  • Epidemiology

Background:

  • Pulmonary alveolar microlithiasis (PAM) is a rare, idiopathic interstitial lung disease of unknown cause.
  • Characterized by the accumulation of tiny calcifications (microliths) in the alveoli.

Purpose of the Study:

  • To update the global literature on Pulmonary alveolar microlithiasis (PAM) cases reported up to the end of 2001.
  • To analyze the epidemiological characteristics, clinical features, diagnostic approaches, and management of PAM.

Main Methods:

  • Comprehensive literature review of all reported PAM cases, including non-English and local language publications, up to December 2001.
  • Analysis of epidemiological data (prevalence, sex distribution, geographic distribution), clinical manifestations, diagnostic techniques (autopsy, biopsy, lavage, imaging), and treatment outcomes.

Main Results:

  • A total of 424 cases were identified: 269 sporadic (male predominant) and 155 familial (female predominant).
  • Europe and Asia (especially Asia Minor) reported the highest number of cases, with Turkey, Italy, and the USA having the most reported cases.
  • Diagnosis has shifted from autopsy to less invasive methods like transbronchial biopsy and bronchoalveolar lavage, with imaging sufficient for familial cases.

Conclusions:

  • Understanding PAM's epidemiology is crucial for improved diagnosis and insights into its unknown etiology and pathogenesis.
  • While no cure exists, lung transplantation is an option for severe cases.